HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
Contemporary antiretroviral therapy (ART) regimens have high barriers to the development
of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of …
of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of …
Islatravir: evaluation of clinical development for HIV and HBV
SW Gillespie, AS Reddy, DM Burris… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor
(NRTTI) that inhibits HIV RT through multiple mechanisms. Contrary to all approved NtRTIs …
(NRTTI) that inhibits HIV RT through multiple mechanisms. Contrary to all approved NtRTIs …
Switch to fixed-dose doravirine (100 mg) with islatravir (0· 75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a …
JM Molina, G Rizzardini, C Orrell, A Afani, A Calmy… - The Lancet …, 2024 - thelancet.com
Background Doravirine and islatravir is an investigational, once-daily, single-tablet regimen
with high antiviral potency, favourable safety and tolerability, and low propensity for …
with high antiviral potency, favourable safety and tolerability, and low propensity for …
Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii
H Wang, A Ishchenko, J Skudlarek, P Shen… - Nature …, 2024 - nature.com
Carbapenem-resistant Acinetobacter baumannii infections have limited treatment options.
Synthesis, transport and placement of lipopolysaccharide or lipooligosaccharide (LOS) in …
Synthesis, transport and placement of lipopolysaccharide or lipooligosaccharide (LOS) in …
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO registry
F Saladini, F Giammarino, F Maggiolo, M Ferrara… - International Journal of …, 2023 - Elsevier
Objectives Doravirine shows a rather distinct resistance profile within the nonnucleoside
reverse transcriptase inhibitor (NNRTI) class. This study aimed to evaluate the phenotypic …
reverse transcriptase inhibitor (NNRTI) class. This study aimed to evaluate the phenotypic …
No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir
TL Diamond, SL Goh, W Ngo, S Rodriguez… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Islatravir (ISL) is a deoxyadenosine analog that inhibits HIV-1 reverse transcription by
multiple mechanisms. Lenacapavir (LEN) is a novel capsid inhibitor that inhibits HIV-1 at …
multiple mechanisms. Lenacapavir (LEN) is a novel capsid inhibitor that inhibits HIV-1 at …
An update on long-acting agents in HIV therapy
L Pezzati, G Canavesi, S Rusconi - Future Virology, 2023 - Taylor & Francis
Since the advent of highly active antiretroviral therapy, many efforts have been made to
broaden the spectrum of possible regimens. Long-acting antiretrovirals, are particularly …
broaden the spectrum of possible regimens. Long-acting antiretrovirals, are particularly …
Novel 2-pyridone Analogs with Anti-cancer Activity: Synthesis, In silico, and In vitro Evaluation
PS Mishra, V Ravichandiran… - Letters in Drug Design & …, 2024 - ingentaconnect.com
Background: 2-pyridone is frequently used to synthesize and develop new bioactive
molecules approved for treating many diseases. The produced compounds play a significant …
molecules approved for treating many diseases. The produced compounds play a significant …
Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure
BG Brenner, M Oliveira, RI Ibanescu… - Journal of …, 2023 - academic.oup.com
Objectives The NNRTI doravirine has been recently approved for the first-line treatment of
HIV-infected patients, eliciting favourable responses against viruses bearing the K103N …
HIV-infected patients, eliciting favourable responses against viruses bearing the K103N …
Die genetische Resistenzbarriere des Humanen Cytomegalovirus gegen den Entry-Inhibitor PDGFR-alpha-Fc
E Ostertag - 2023 - oparu.uni-ulm.de
Das humane Cytomegalovirus (HCMV) kann sowohl bei intrauteriner Infektion eines Fetus
als auch bei einer Infektion unter Immunsuppression schwere Erkrankungen hervorrufen …
als auch bei einer Infektion unter Immunsuppression schwere Erkrankungen hervorrufen …